May 13 |
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
|
May 13 |
UroGen Pharma GAAP EPS of -$0.97 misses by $0.08, revenue of $18.78M misses by $2.61M
|
May 13 |
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
|
May 12 |
Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
|
May 10 |
UroGen Pharma Q1 2024 Earnings Preview
|
May 5 |
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
|
May 4 |
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
|
May 4 |
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
|
May 3 |
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
|
Apr 22 |
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
|